ETNB

89bio, Inc.

11.17 USD
-0.01 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

89bio, Inc. stock is up 9.83% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 February’s closed higher than January. In the last 5 Unusual Options Trades, there were 4 CALLs, 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Dec 17:26 21 Jun, 2024 10.00 CALL 100 220
28 Dec 18:21 17 Jan, 2025 12.50 CALL 80 1
10 Jan 20:57 17 Jan, 2025 15.00 CALL 100 227
29 Jan 15:22 15 Mar, 2024 12.50 CALL 5000 4
14 Feb 16:15 17 May, 2024 15.00 PUT 150 37

About 89bio, Inc.

89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.